首页> 外文OA文献 >Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma

【2h】

Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma

机译：在新诊断的多发性骨髓瘤患者自体造血干细胞移植后，硼替佐米-沙利度胺-地塞米松在巩固治疗方面优于沙利度胺-地塞米松

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Cavo Michele; Pantani Lucia; Petrucci Maria Teresa; Patriarca Francesca; Zamagni Elena; Donnarumma Daniela; Crippa Claudia; Boccadoro Mario; Perrone Giulia; Falcone Antonietta; Nozzoli Chiara; Zambello Renato; Masini Luciano; Furlan Anna; Brioli Annamaria; Derudas Daniele; Ballanti Stelvio; Dessanti Maria Laura; De Stefano Valerio; Carella Angelo Michele; Marcatti Magda; Nozza Andrea; Ferrara Felicetto; Callea Vincenzo; Califano Catello; Pezzi Annalisa; Baraldi Anna; Grasso Mariella; Musto Pellegrino; Palumbo Antonio; la Nasa G;
展开▼
作者单位

展开▼
年度 2012
总页数
原文格式 PDF
正文语种 eng
中图分类

相似文献

外文文献
中文文献
专利

1. Bortezomib-thalidomide-dexamethasone is superior to thalidomide- dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma [J] . CavoM., PantaniL., PetrucciM.T., Blood: The Journal of the American Society of Hematology . 2012,第1期

机译：新诊断的多发性骨髓瘤患者自体造血干细胞移植后，硼替佐米-沙利度胺-地塞米松优于沙利度胺-地塞米松巩固治疗
2. Bortezomib-Thalidomide-Dexamethasone Versus Thalidomide-Dexamethasone before and after Double Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Final Analysis of Phase 3 Gimema-MMY-3006 Study and Prognostic Score for Survival Outcomes [J] . Tacchetti Paola, Dozza Luca, Di Raimondo Francesco, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：Bortezomib-羟胺 - 地塞米松与亚马亚多胺 - 地塞米松，双重自体干细胞移植前后进行新诊断的多发性骨髓瘤：最终分析3阶段3毫米-3006研究和预后分数的生存结果
3. Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency. [J] . Tosi P, Zamagni E, Tacchetti P, Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2010,第8期

机译：沙利度胺-地塞米松作为新诊断为多发性骨髓瘤和肾功能不全的患者自体干细胞移植前的诱导疗法。
4. HIGH DOSE THERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) FOR PATIENTS WITH PRIMARY SYSTEMIC AMYLOIDOSIS (AL): AN ABMTR STUDY [C] . DH Vesole, W Perez, D Reece, International Symposium on Amyloidosis . 2005

机译：具有自体造血干细胞移植（HSCT）的高剂量治疗用于初级全身淀粉样蛋白症（AL）的患者：ABMTR研究
5. Posttraumatic stress disorder and sub-syndromal trauma symptoms in cancer patients treated with autologous hematopoietic stem cell transplant and standard dose chemotherapy. [D] . Gourvitz, Ross L. 2008

机译：自体造血干细胞移植和标准剂量化疗治疗的癌症患者的创伤后应激障碍和综合征下创伤症状。
6. Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials [O] . Mohamed A Kharfan-Dabaja, Mehdi Hamadani, Tea Reljic, 2013

机译：自体串联与自体串联同种异体造血细胞移植在新诊断多发性骨髓瘤患者中的比较疗效：随机对照试验的系统评价和荟萃分析
7. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma [O] . Cavo, M, Pantani, L, Petrucci, M, 2012

机译：在新诊断的多发性骨髓瘤患者自体造血干细胞移植后，硼替佐米-沙利度胺-地塞米松在巩固治疗方面优于沙利度胺-地塞米松

Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma

著录项

引文网络

相似文献

相关主题

期刊订阅